MedTrace Logo

COMPARATIVE ANALYSIS OF INNOVATIVE BONE HEALING TECHNIQUES

NCT05480631 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-07-29

No results posted yet for this study

Summary

the study intends to observe the outcome of interventions (concentrated growth factor with autograft and xenograft) used to expedite bone healing and adaptation with minimal side effects. Three different modalities are being used to bridge the mandibular fracture defects (\>5mm-\<5cm). Those modalities include group A- autograft, group B-autograft with concentrated growth factor, and group C- xenograft with concentrated growth factor. the outcomes are measured in terms of acquired bone density (Hounsfield unit) that is obtained at the 4th and 6th month post-operatively via cone-beam computed tomography.

Conditions

  • To Assess the Bone Healing in Fracture Mandible Defects

Interventions

PROCEDURE

autograft

autologous bone placed in the defect and then be secured with mini-screws to fill the fracture defect gap

PROCEDURE

autograft with addition of concenterated growth factor

the bone particulate harvested from the donor site will then be mixed with concentrated growth factor to bridge the fracture defect.

PROCEDURE

xenograft with concentrated growth factor

xenogenic bovine bone particulate mixed with platelet-derived concentrated growth factor to be held in place of fracture defect site.

Sponsors & Collaborators

  • Dow University of Health Sciences

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-17
Primary Completion
2022-07-20
Completion
2022-07-20

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05480631 on ClinicalTrials.gov